Lytix Biopharma secures non-dilutive funding for advanced melanoma research.

NORDIC BUSINESS REPORT-October 17, 2023-Lytix Biopharma secures non-dilutive funding for advanced melanoma research

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Clinical stage immuno-oncology company Lytix Biopharma (Euronext Growth Oslo: LYTIX) announced on Tuesday that it has secured NOK14.3m (USD1.3m) in non-dilutive funding from the 'SkatteFUNN' R&D tax incentive scheme, endorsed by the Research Council of Norway.

The funding supports Lytix's lead program 'Intratumoral LTX-315 in advanced melanoma.' This approval enables Lytix to claim tax deductions for documented research and...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT